|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
JP2008519863A
(ja)
|
2004-11-12 |
2008-06-12 |
シアトル ジェネティクス インコーポレイティッド |
Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
|
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
PL2099823T5
(pl)
|
2006-12-01 |
2023-02-20 |
Seagen Inc. |
Wariant środków wiążących cel i jego zastosowania
|
|
AU2008230795B2
(en)
|
2007-03-27 |
2014-05-29 |
Bioassets, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
PT2474557E
(pt)
|
2007-07-16 |
2014-12-03 |
Genentech Inc |
Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
|
|
PE20140625A1
(es)
|
2007-07-16 |
2014-05-29 |
Genentech Inc |
ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
|
|
CN101903403B
(zh)
|
2007-10-19 |
2016-03-16 |
西雅图基因公司 |
Cd19结合剂及其应用
|
|
DK2657253T3
(en)
|
2008-01-31 |
2017-10-09 |
Genentech Inc |
Anti-CD79b antibodies and immune conjugates and methods of use
|
|
PL2282773T3
(pl)
|
2008-05-02 |
2014-08-29 |
Seattle Genetics Inc |
Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
|
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
|
MY173390A
(en)
|
2009-10-23 |
2020-01-22 |
Takeda Pharmaceuticals Co |
Anti-gcc antibody molecules and related compositions and methods
|
|
BR112012019780A2
(pt)
*
|
2010-02-08 |
2020-09-01 |
Agensys, Inc. |
conjugados de fármaco e anticorpo (adc) que ligam a proteínas 161p2f10b
|
|
WO2011109308A1
(en)
*
|
2010-03-02 |
2011-09-09 |
Seattle Genetics, Inc. |
Methods for screening antibodies
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
EP3513794A3
(en)
|
2010-08-05 |
2019-10-16 |
Seattle Genetics, Inc. |
Fucose analogs for inhibition of protein fucosylation in vivo
|
|
US9303083B2
(en)
*
|
2010-10-04 |
2016-04-05 |
Riken |
Therapeutic agent for malignant tumors expressing MHC class II
|
|
JP6121906B2
(ja)
|
2010-10-22 |
2017-04-26 |
シアトル ジェネティクス，インコーポレーテッド |
アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴｍＴＯＲ経路インヒビターの間の相乗効果
|
|
SG191233A1
(en)
|
2010-12-23 |
2013-07-31 |
Janssen Biotech Inc |
Active protease-resistant antibody fc mutants
|
|
CN103403621B
(zh)
|
2010-12-23 |
2015-11-25 |
尤利塔股份公司 |
用于在大面积上产生纳米结构的系统和方法
|
|
HUE031017T2
(en)
*
|
2011-04-01 |
2017-06-28 |
Wyeth Llc |
Antibody Drug Conjugates
|
|
EP2717916B1
(en)
|
2011-06-10 |
2017-03-08 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
CA2842860A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies, Llc |
Sur-binding proteins
|
|
CA2841738C
(en)
|
2011-08-16 |
2022-12-06 |
Morphosys Ag |
Combination therapy with an anti-cd19 antibody and a purine analog
|
|
SG10201606785UA
(en)
|
2011-08-16 |
2016-10-28 |
Morphosys Ag |
Combination therapy with an anti - cd19 antibody and a nitrogen mustard
|
|
CN102343083A
(zh)
*
|
2011-10-17 |
2012-02-08 |
中国科学院成都生物研究所 |
一种抗病毒的组合药物
|
|
WO2013067581A1
(en)
*
|
2011-11-09 |
2013-05-16 |
Children's Cancer Institute Australia for Medical Research |
Cancer treatment
|
|
US9975956B2
(en)
|
2011-12-22 |
2018-05-22 |
I2 Pharmaceuticals, Inc. |
Surrogate binding proteins which bind DR4 and/or DR5
|
|
AU2013209512B2
(en)
|
2012-01-20 |
2017-08-03 |
I2 Pharmaceuticals, Inc. |
Surrobody cojugates
|
|
AU2013216863B2
(en)
|
2012-02-10 |
2018-09-06 |
Seagen Inc. |
Detection and treatment of CD30+ cancers
|
|
CN104822656B
(zh)
|
2012-05-15 |
2018-05-01 |
西雅图基因公司 |
自稳定接头偶联物
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
US20150182490A1
(en)
|
2012-06-26 |
2015-07-02 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
|
IN2014DN10889A
(enExample)
*
|
2012-07-13 |
2015-09-11 |
Univ Pennsylvania |
|
|
PT2692865E
(pt)
|
2012-07-30 |
2015-02-06 |
Nbe Therapeutics Llc |
Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
|
|
EP2887947B1
(en)
|
2012-08-23 |
2019-06-05 |
Seattle Genetics, Inc. |
Fucose analogues for the treatment of sickle cell disease
|
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
|
DK2839860T3
(da)
|
2012-10-12 |
2019-06-17 |
Medimmune Ltd |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
ES2623209T3
(es)
|
2012-10-24 |
2017-07-10 |
Polytherics Limited |
Conjugados fármaco-proteína
|
|
NO2789793T3
(enExample)
*
|
2012-10-24 |
2018-01-27 |
|
|
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
WO2014100740A1
(en)
|
2012-12-21 |
2014-06-26 |
Seattle Genetics, Inc. |
Anti-ntb-a antibodies and related compositions and methods
|
|
ES2687439T3
(es)
|
2013-03-13 |
2018-10-25 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
EP2777714A1
(en)
|
2013-03-15 |
2014-09-17 |
NBE-Therapeutics LLC |
Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
|
|
US9840560B2
(en)
*
|
2013-03-15 |
2017-12-12 |
Alper Biotech Llc |
Monoclonal antibodies to EGFR, and uses therefor
|
|
UY35468A
(es)
*
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CN105492011A
(zh)
|
2013-04-08 |
2016-04-13 |
丹尼斯·M·布朗 |
不理想给药化学化合物的治疗增效
|
|
SI2997141T1
(sl)
*
|
2013-05-13 |
2023-04-28 |
Cellectis |
CD19 specifični himerni antigenski receptor in njegova uporaba
|
|
PT3057585T
(pt)
|
2013-10-15 |
2020-10-21 |
Seagen Inc |
Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
|
|
WO2015095301A2
(en)
|
2013-12-17 |
2015-06-25 |
Irm Llc |
Cytotoxic peptides and conjugates thereof
|
|
MX2016010295A
(es)
|
2014-02-11 |
2016-10-17 |
Seattle Genetics Inc |
Reduccion selectiva de proteinas.
|
|
EP3107557B1
(en)
|
2014-02-17 |
2021-06-09 |
Seagen Inc. |
Hydrophilic antibody-drug conjugates
|
|
CN111499753B
(zh)
|
2014-03-03 |
2022-10-21 |
高雄医学大学 |
双功能抗体及其用途
|
|
TW201622743A
(zh)
|
2014-03-19 |
2016-07-01 |
財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 |
免疫原醣肽、包含該醣肽之組合物及其用途
|
|
CA2942150A1
(en)
*
|
2014-04-07 |
2015-10-15 |
Seattle Genetics, Inc. |
Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
|
|
CN106170300A
(zh)
*
|
2014-04-08 |
2016-11-30 |
西雅图基因公司 |
Cd19‑抗体药物偶联物的优化给药
|
|
US9884817B2
(en)
|
2014-06-13 |
2018-02-06 |
Novartis Ag |
Auristatin derivatives and conjugates thereof
|
|
US10973920B2
(en)
|
2014-06-30 |
2021-04-13 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
SG11201701565PA
(en)
|
2014-09-03 |
2017-03-30 |
Immunogen Inc |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
HRP20241124T1
(hr)
|
2014-09-11 |
2024-11-22 |
Seagen Inc. |
Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin
|
|
CA2979671C
(en)
|
2014-09-23 |
2020-03-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
EA201790719A1
(ru)
*
|
2014-09-26 |
2017-07-31 |
Макродженикс, Инк. |
Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
US20180028681A1
(en)
*
|
2015-02-12 |
2018-02-01 |
Seattle Genetics, Inc. |
Combination therapy using a cd19-adc and vincristine
|
|
KR20170128256A
(ko)
|
2015-03-18 |
2017-11-22 |
시애틀 지네틱스, 인크. |
Cd48 항체 및 이의 접합체
|
|
JP6916741B2
(ja)
|
2015-05-26 |
2021-08-11 |
モルフォシス・アーゲー |
抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用
|
|
CN116726190A
(zh)
*
|
2015-06-20 |
2023-09-12 |
杭州多禧生物科技有限公司 |
澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
|
|
KR20180021705A
(ko)
|
2015-06-30 |
2018-03-05 |
시애틀 지네틱스, 인크. |
항-ntb-a 항체 및 관련 조성물 및 방법
|
|
AU2016311136B2
(en)
|
2015-08-21 |
2022-02-17 |
Incyte Corporation |
Combinations and uses thereof
|
|
EP4400507B1
(en)
*
|
2015-09-08 |
2026-08-05 |
Waters Technologies Corporation |
Multidimensional chromatography method for analysis of antibody-drug conjugates
|
|
EP3747472B1
(en)
|
2015-09-15 |
2024-04-03 |
Acerta Pharma B.V. |
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
CN108283001B
(zh)
|
2015-10-08 |
2022-08-19 |
酵活有限公司 |
包含κ和λ轻链的抗原结合多肽构建体及其用途
|
|
IL258491B2
(en)
|
2015-10-16 |
2023-09-01 |
Univ Columbia |
Preparations and methods for inhibiting antigens of a particular lineage
|
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
US11229708B2
(en)
|
2015-12-04 |
2022-01-25 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
MA44254A
(fr)
|
2016-02-17 |
2018-12-26 |
Seattle Genetics Inc |
Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
|
|
WO2017160954A1
(en)
|
2016-03-15 |
2017-09-21 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
|
|
EP3433278A4
(en)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
|
|
US20190112380A1
(en)
*
|
2016-03-29 |
2019-04-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
ES2981046T3
(es)
|
2016-05-30 |
2024-10-07 |
Incyte Corp |
Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
|
|
SMT202100317T1
(it)
|
2016-06-27 |
2021-07-12 |
Morphosys Ag |
Formulazioni di anticorpi anti-cd19
|
|
KR20230047507A
(ko)
|
2016-06-27 |
2023-04-07 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|
|
EP3487525A4
(en)
*
|
2016-07-22 |
2020-03-18 |
Seattle Genetics, Inc. |
COMBINATION THERAPY WITH CD19-ADC AND RCHP
|
|
KR20240010534A
(ko)
|
2016-08-09 |
2024-01-23 |
씨젠 인크. |
개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CN109862919A
(zh)
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
|
EA201990890A1
(ru)
|
2016-10-18 |
2019-10-31 |
|
Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
|
|
WO2018078123A1
(en)
|
2016-10-28 |
2018-05-03 |
Morphosys Ag |
Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
|
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
CN108452318B
(zh)
*
|
2017-02-17 |
2023-05-26 |
浙江特瑞思药业股份有限公司 |
靶向cd20的抗体偶联药物及其制备方法和用途
|
|
KR102709603B1
(ko)
|
2017-02-28 |
2024-09-27 |
보르 바이오파마 인크. |
계통 특이적 단백질의 억제를 위한 조성물 및 방법
|
|
SG11201907288RA
(en)
|
2017-02-28 |
2019-09-27 |
Seattle Genetics Inc |
Cysteine mutated antibodies for conjugation
|
|
JP7527787B2
(ja)
|
2017-03-24 |
2024-08-05 |
シージェン インコーポレイテッド |
グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
WO2018201087A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
CN111010867B
(zh)
|
2017-05-30 |
2023-05-12 |
俄克拉何马大学董事会 |
抗双皮层蛋白样激酶1抗体及其使用方法
|
|
HUE063119T2
(hu)
|
2017-05-31 |
2024-01-28 |
Morphosys Ag |
Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez
|
|
WO2019011918A1
(en)
|
2017-07-10 |
2019-01-17 |
International - Drug - Development - Biotech |
TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
|
|
CA3072153A1
(en)
*
|
2017-08-10 |
2019-02-14 |
Sumitomo Dainippon Pharma Co., Ltd. |
Antibody-drug conjugates including hemiasterlin derivative
|
|
CN111051329B
(zh)
*
|
2017-08-10 |
2024-07-30 |
住友制药株式会社 |
哈米特林衍生物及它们的抗体药物复合物
|
|
CN109535253B
(zh)
*
|
2017-09-21 |
2022-11-04 |
上海药明生物技术有限公司 |
新型抗cd19抗体
|
|
CN109535257B
(zh)
|
2017-09-22 |
2021-05-28 |
同润生物医药(上海)有限公司 |
新型双特异性cd3/cd19多肽复合物
|
|
EP3694883A1
(en)
|
2017-10-12 |
2020-08-19 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
CA3084495A1
(en)
|
2017-12-01 |
2019-06-06 |
Seattle Genetics, Inc. |
Humanized anti-liv1 antibodies for the treatment of breast cancer
|
|
AR113862A1
(es)
|
2017-12-01 |
2020-06-17 |
Seattle Genetics Inc |
Anticuerpos anti-cd47 y sus usos para tratar cáncer
|
|
WO2019119822A1
(en)
*
|
2017-12-23 |
2019-06-27 |
Uwell Biopharma Inc. |
Pharmaceutical chimeric receptor composition and method thereof
|
|
EP3735252A4
(en)
*
|
2018-01-04 |
2021-10-06 |
Avidity Biosciences, Inc. |
HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
WO2019183438A1
(en)
|
2018-03-23 |
2019-09-26 |
Seattle Genetics, Inc. |
Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
TWI920652B
(zh)
|
2018-06-07 |
2026-04-01 |
美商思進公司 |
喜樹鹼結合物
|
|
BR112021001750A2
(pt)
|
2018-08-06 |
2021-04-27 |
Daiichi Sankyo Company, Limited |
composição farmacêutica
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
KR20200030337A
(ko)
|
2018-09-12 |
2020-03-20 |
주식회사 녹십자랩셀 |
종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
|
|
BR112021008486A2
(pt)
*
|
2018-11-01 |
2021-10-26 |
Shandong New Time Pharmaceutical Co., Ltd |
Anticorpo biespecífico e seu uso
|
|
CA3128368A1
(en)
*
|
2019-02-01 |
2020-08-06 |
Memorial Sloan Kettering Cancer Center |
Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
|
|
JP7754715B2
(ja)
|
2019-02-05 |
2025-10-15 |
シージェン インコーポレイテッド |
抗ｃｄ２２８抗体及び抗体薬物コンジュゲート
|
|
US12178879B2
(en)
|
2019-02-13 |
2024-12-31 |
Sumitomo Pharma Co., Ltd. |
Hemiasterlin derivative and antibody-drug conjugate thereof
|
|
CN113412271B
(zh)
|
2019-02-13 |
2024-10-22 |
住友制药株式会社 |
具有半胱氨酸残基的哈米特林衍生物
|
|
JP7560255B2
(ja)
*
|
2019-02-13 |
2024-10-02 |
住友ファーマ株式会社 |
ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
|
|
WO2020213084A1
(en)
|
2019-04-17 |
2020-10-22 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
|
CN114072424A
(zh)
|
2019-05-03 |
2022-02-18 |
莫佛塞斯公司 |
具有有限数量的nk细胞的患者中的抗cd19疗法
|
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
|
CN110128551A
(zh)
*
|
2019-06-05 |
2019-08-16 |
上海科弈药业科技有限公司 |
一种针对cd19+肿瘤的多功能融合蛋白及其应用
|
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
TW202112801A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
純化遮蔽抗體之方法
|
|
MX2022000853A
(es)
|
2019-07-22 |
2022-03-17 |
Seagen Inc |
Anticuerpos anti-liv1 humanizados para el tratamiento de cancer.
|
|
BR112022005114A2
(pt)
|
2019-10-04 |
2022-06-21 |
Seagen Inc |
Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
WO2021084062A1
(en)
|
2019-10-31 |
2021-05-06 |
Morphosys Ag |
Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
|
|
LT4051710T
(lt)
|
2019-10-31 |
2026-03-10 |
Incyte Corporation |
Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles
|
|
CN115916818A
(zh)
*
|
2019-12-11 |
2023-04-04 |
库利南肿瘤股份有限公司 |
抗cd19抗体和多特异性结合蛋白
|
|
US20230032087A1
(en)
*
|
2019-12-11 |
2023-02-02 |
Cullinan Oncology, Inc. |
Anti-serum albumin antibodies
|
|
CA3173980A1
(en)
*
|
2020-03-03 |
2021-09-10 |
Systimmune, Inc. |
Anti-cd19 antibodies and methods of using and making thereof
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
AU2021251875A1
(en)
|
2020-04-10 |
2022-11-03 |
Seagen Inc. |
Charge variant linkers
|
|
EP4168449A1
(en)
|
2020-06-22 |
2023-04-26 |
MorphoSys AG |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
|
|
AU2021320739A1
(en)
|
2020-08-04 |
2023-02-23 |
Seagen Inc. |
Anti-CD228 antibodies and antibody-drug conjugates
|
|
TW202229346A
(zh)
|
2020-09-28 |
2022-08-01 |
美商西根公司 |
用於治療癌症之人化抗ｌｉｖ１抗體
|
|
TWI914420B
(zh)
|
2020-10-06 |
2026-02-11 |
美商山可爾股份有限公司 |
用於治療包括全身性紅斑性狼瘡(sle)的自體免疫疾病之生物標記、方法及組合物
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
TW202233248A
(zh)
|
2020-11-08 |
2022-09-01 |
美商西健公司 |
組合療法
|
|
AU2021391623A1
(en)
|
2020-12-04 |
2023-06-29 |
Incyte Corporation |
Anti-cd19 combination therapy
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
JP2024510435A
(ja)
|
2021-03-18 |
2024-03-07 |
シージェン インコーポレイテッド |
生体活性化合物の内部移行複合体からの選択的薬物放出
|
|
IL308296A
(en)
*
|
2021-05-07 |
2024-01-01 |
Viela Bio Inc |
Use of anti-CD19 antibody to treat myasthenia gravis
|
|
US20240352080A1
(en)
|
2021-07-14 |
2024-10-24 |
Seagen Inc. |
Antibody Masking Domains
|
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
|
WO2023073645A1
(en)
|
2021-10-29 |
2023-05-04 |
Takeda Pharmaceutical Company Limited |
Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
WO2023108102A1
(en)
*
|
2021-12-10 |
2023-06-15 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Anti-lcn-2 antibodies as a treatment for eye disorders
|
|
KR20250004952A
(ko)
|
2022-03-17 |
2025-01-08 |
씨젠 인크. |
캄프토테신 접합체
|
|
WO2023245106A1
(en)
|
2022-06-16 |
2023-12-21 |
Abbvie Biotherapeutics Inc. |
Anti-cd19 antibody drug conjugates
|
|
IL318787A
(en)
|
2022-08-17 |
2025-04-01 |
Incyte Corp |
Treatment including ANTI-CD19 antibodies and EZH2 modulators
|
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
|
JP2025537099A
(ja)
|
2022-11-03 |
2025-11-14 |
シージェン インコーポレイテッド |
抗αＶβ６抗体および抗体－薬物コンジュゲートならびにがんの治療におけるそれらの使用
|
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
KR20250145079A
(ko)
|
2023-02-09 |
2025-10-13 |
비원 메디슨즈 아이 게엠베하 |
자가 안정화 링커 접합체
|
|
JP2026511515A
(ja)
|
2023-03-23 |
2026-04-14 |
ビーワン メディシンズ ワン ゲーエムベーハー |
生体活性コンジュゲートならびにその調製方法及びその使用
|
|
PE20260290A1
(es)
|
2023-03-31 |
2026-02-10 |
Abelzeta Inc |
Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
TW202545992A
(zh)
|
2024-01-23 |
2025-12-01 |
中國大陸商上海藥明生物技術有限公司 |
靶向ｃｄ３、ｃｄ１９及ｃｄ２０之多特異性抗體及其用途
|
|
TW202545567A
(zh)
|
2024-01-30 |
2025-12-01 |
美商思進公司 |
抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
|
|
US20250295801A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody drug conjugates, and uses thereof
|
|
CN121622852B
(zh)
*
|
2026-02-05 |
2026-05-29 |
杭州康源食品科技有限公司 |
具有调节免疫补气血的蛋清蛋白来源小分子肽及其应用
|